SPDYA and breast cancer: Since ERK1/2 activation significantly promotes uncontrolled cell growth, survival, and invasion, determining a way to suspend ERK1/2 activation by Spy1 could have clinical implications for tamoxifen resistance and breast cancer therapies in at least subsets of patients.